Skip to Main Content

Paper Details

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma.
Front Oncol
4
2023
GBM, NLRP3, NO, RRx, RRx-, RRx-001, SCLC, TMZ, glioblastoma, high grade gliomas, macrophage, nitric oxide, patients, small cell lung cancer, temozolomide
Author NameAffiliation
Howard A FineBrain Tumor Center at New York-Presbyterian Weill Cornell Medical Center
Nicholas Butowski
Nicholas Butowski
  • 1 - 3

Datasets

Release 1.2